Vabysmo shows 4-year durability in wet AMD and 60% lesion clearance in PCV: What the new Genentech data reveals

Genentech, the South San Francisco-based biotechnology company and a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has presented pivotal new data from its long-term retinal disease program for Vabysmo® (faricimab-svoa), a bispecific antibody therapy designed for vision-threatening conditions like neovascular (wet) age-related macular degeneration.

The latest results, disclosed at the 25th Euretina Congress in Paris, include four-year efficacy and durability data from the AVONELLE-X extension study, alongside one-year visual and anatomical outcomes from the SALWEEN trial focused on polypoidal choroidal vasculopathy—a particularly aggressive subtype of wet AMD seen in Asian populations.

Genentech emphasized that these data further validate the durability and safety of Vabysmo, especially its ability to reduce treatment burden through extended dosing intervals without compromising visual outcomes. According to the company, nearly 80% of patients in AVONELLE-X were able to maintain disease control on three- to four-month intervals by study end. Meanwhile, in SALWEEN, more than 60% of patients exhibited full resolution of characteristic polypoidal lesions, and over 50% were successfully transitioned to five-month dosing intervals.

What long-term insights did the AVONELLE-X study provide about Vabysmo’s ability to sustain vision in wet AMD patients?

AVONELLE-X was designed as a two-year, open-label extension study for participants who had completed the initial two-year Phase III trials TENAYA and LUCERNE. These earlier pivotal studies compared Vabysmo to aflibercept and demonstrated non-inferiority in visual outcomes, while enabling longer intervals between injections.

In AVONELLE-X, all 1,029 enrolled patients were treated with Vabysmo using a “treat-and-extend” protocol based on anatomical markers and visual acuity. The results revealed continued visual stability over the full four-year period. Anatomical gains—including reduced retinal fluid and improved central subfield thickness—were also maintained throughout.

Genentech stated that nearly 80% of patients achieved dosing intervals of every three or four months by the end of the trial. Importantly, this confirms that the durability signal observed in the parent studies holds over longer durations. The safety profile remained consistent, with no new adverse events reported.

For clinicians managing wet AMD—one of the leading causes of blindness in older adults—the data represents a significant step toward reducing the high burden of monthly anti-VEGF injections without sacrificing long-term outcomes.

How did the SALWEEN trial highlight Vabysmo’s impact on polypoidal choroidal vasculopathy common in Asian patients?

The SALWEEN study addressed a critical unmet need in ophthalmology: managing PCV, a difficult-to-treat subtype of wet AMD marked by abnormal polyp-like blood vessels in the choroid. This condition is far more prevalent among people of Asian descent and is associated with more aggressive disease progression and poorer visual prognosis if untreated or undertreated.

Conducted across 38 sites in nine Asian countries—including China, Japan, India, Singapore, and South Korea—the Phase IIIb/IV SALWEEN trial enrolled 135 participants aged 50 and older. Each received four loading doses of Vabysmo 6 mg over 12 weeks, followed by personalized dosing every 8, 12, or 16 weeks based on treatment response. From weeks 44 to 104, intervals could extend up to 20 weeks for stable patients.

At the one-year mark, patients gained an average of 8.9 letters in best-corrected visual acuity (BCVA). Beyond vision improvement, anatomical gains were notable: over 60% of participants experienced complete resolution of polypoidal lesions, and lesion inactivation was observed in 86% of cases. More than half of patients transitioned to dosing intervals of five months.

The data from SALWEEN are particularly significant given the scarcity of robust PCV-specific clinical evidence in the anti-VEGF class. Genentech’s results indicate that Vabysmo can potentially become a preferred option in Asia-Pacific markets where PCV accounts for up to 60% of wet AMD diagnoses.

Why are these results important for the future of Vabysmo in global ophthalmology markets?

With more than eight million Vabysmo doses distributed since its U.S. launch in 2022, and regulatory approvals spanning over 100 countries for wet AMD and diabetic macular edema (DME), Genentech has steadily positioned the drug as a foundational therapy for retinal vascular disease. The AVONELLE-X and SALWEEN data further extend the narrative: that Vabysmo offers a combination of durability, anatomical control, and extended dosing potential across multiple disease subtypes.

What makes Vabysmo unique is its bispecific mechanism targeting both VEGF-A and angiopoietin-2 (Ang-2), two pathways implicated in vessel destabilization, fluid leakage, and retinal inflammation. This dual-target approach, Genentech claims, contributes to longer-lasting disease control with fewer injections than traditional monotherapies.

These attributes are strategically important in the context of healthcare cost pressures and rising AMD incidence globally. By reducing the frequency of injections from monthly to potentially once every four or five months, Vabysmo presents a compelling value proposition for payers, clinicians, and patients alike.

How do institutional investors and analysts interpret the durability and safety signals from Vabysmo’s latest trials?

Although no specific equity research firms were quoted, institutional sentiment has broadly trended positive on Vabysmo in previous quarters, particularly following real-world data presented in 2024 showing extended dosing intervals and consistent safety in routine practice.

The durability demonstrated in AVONELLE-X strengthens the case for long-term commercial sustainability. With fewer injections and clinic visits required, patient adherence is expected to improve, which may in turn support better real-world outcomes—often a weak point in chronic ophthalmic care.

In the SALWEEN trial, the confirmation of efficacy in PCV unlocks strategic geographic potential across Asia-Pacific markets where Genentech and Roche are already expanding local ophthalmology infrastructure. Analysts covering large-cap biopharma names have pointed to Vabysmo’s role in strengthening Roche’s post-Lucentis franchise lifecycle and competing with newer entrants in the anti-VEGF space.

What does the future outlook look like for patients and clinicians adopting Vabysmo for neovascular retinal diseases?

Looking ahead, Vabysmo is well-positioned to become a backbone therapy in the retinal disease space—especially as data accumulates for additional subgroups such as retinal vein occlusion and geographic atrophy.

Physicians treating wet AMD are likely to become increasingly confident prescribing Vabysmo on personalized dosing schedules, as AVONELLE-X offers robust evidence that longer intervals do not compromise safety or efficacy. In regions where PCV dominates the AMD landscape, such as Southeast Asia and East Asia, SALWEEN could drive increased uptake through clearer lesion resolution data.

Meanwhile, Genentech continues to support access through programs like Genentech Access Solutions and education initiatives targeting underdiagnosed retinal conditions.

For patients, the combination of fewer injections, meaningful vision improvement, and stable safety may translate to better quality of life, increased independence, and reduced travel or care coordination burden—especially for elderly individuals who often struggle with high-frequency treatment regimens.